Personalized wound healing
Diabetic foot ulcers have a debilitating impact on patients. Despite numerous treatment options, about 60% of all patients experience a wound that does not heal.46 If the severity of a wound progresses to grade 4 or 5, the cost of treatment is eight times higher than a grade 1 or 2 wound.47 For about 20% of patients, treatment ends in amputation within one year.48
At Reapplix, we have established that one of the keys to successful wound treatment lies in the body’s capacity to heal – and each patient is central to that process. Using just a small sample of the patient’s blood – nothing else – the 3C Patch® System separates, coagulates and compacts the blood components into a solid patch. The result is a single 3C Patch® comprising a concentration of proteins, active cells and growth factors.
Each 3C Patch® takes about 20 minutes to produce and is applied directly to the wound at point-of-care. One of few evidence-based wound treatments, the 3C Patch® is clinically proven to significantly accelerate wound healing of hard-to-heal diabetic foot ulcers.1 The outcome is a cost-effective, personalized wound treatment that draws on each patient’s unique ability to help their own healing process.
Every wound is personal.
Truly autologous with no reagents or additives
A small blood sample is drawn directly into the 3C Patch® device. No additives are needed.
The nurse places the blood sample directly into the 3CP® Centrifuge. The process takes about 20 minutes.
After the 3CP process is complete the moist 3C Patch® is ready.
The 3C Patch® is applied directly to the wound. Multiple patches can be used for larger wounds.
Large public healthcare cost
In Europe, the heavy costs from diabetic foot ulcers and complications exceed those of major cardiac diseases.2
In the US, recent estimates of the cost to Medicare for DFUs range from 6.2 billion USD when the DFU is the primary diagnosis up to 18.7 billion USD with secondary diagnoses.3
The number of people in the world with diabetes has nearly quadrupled in the past 40 years and data show their lifetime risk of developing a foot ulcer is currently 25%.1
Lifetime risk of foot ulcer for any diabetic is around 25%
In July 2018, Reapplix moved forward, based on the strong clinical results of the recent independent RCT, and has formed Reapplix Inc. based in Texas to bring the 3C Patch® System onto the US market.
Developing innovative solutions needed to help patients and society while also creating successful business is in the DNA of inventor Niels Erik Holm who is also known for inventing several successful medical devices (Insulin Infusion Set, Feeding tubes, Novolet Pen, Vivostat System, Seroma Set) and for generating over 60 patents. The NovoLet pen has sold over 750 million units.
Reapplix’s co-founders Niels Erik Holm and Rasmus Lundquist are both experienced and successful entrepreneurs driven to bring their proven value-based healthcare solution onto the market. Rasmus Lundquist, Reapplix’s Chief Scientific Officer, co-founded RAM Biotech Aps in 2001 prior to joining Reapplix and has a M.Sc. in biology and immunology from Copenhagen University and a graduate certificate in Bio Design from Stanford University.
Niels Erik Holm, Reapplix’s founder also invented the NovoLet pen, which has helped millions of diabetic patients all over the world since its introduction in the 1980s. Photo: Scanpix
1. Hurlow JJ, Humphreys GJ, Bowling FL, McBain AJ, “Diabetic foot infection: A critical complication.” Int Wound J.2018 Oct: 15(5):814-821 doi: 10.1111/iwj.12932. Epub 2018 May 28
2. Tchero H, Kangeambega P, Lin L, Mukisi-Mukaza M, Brunet-Houdard S, Briatte C, Retali GR, Rusch E, “Cost of diabetic foot in France, Spain, Italy, Germany and United Kingdom: A systematic review.” Ann Endocrinol (Paris). 2018 Apr.79 (2): 67-73 doi: 10.1016/j.ando.2017.11.005 . Epub 2018 Mar 12
3. Nussbaum SR, Carter MJ, Fife CE, DaVanzo J, Haught R, Nusgart M, Cartwright D., “An Economic Evaluation of the Impact, Cost, and Medicare Policy Implications of Chronic Nonhealing Wounds.” Value Health, 2018 Jan: 21(1) 25-32: 10.1016/jval.2017.07.007. E pub 2017 Sep 19